IL114914A0 - Modulation of cellular activity - Google Patents
Modulation of cellular activityInfo
- Publication number
- IL114914A0 IL114914A0 IL11491495A IL11491495A IL114914A0 IL 114914 A0 IL114914 A0 IL 114914A0 IL 11491495 A IL11491495 A IL 11491495A IL 11491495 A IL11491495 A IL 11491495A IL 114914 A0 IL114914 A0 IL 114914A0
- Authority
- IL
- Israel
- Prior art keywords
- modulation
- cellular activity
- cellular
- activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002131130A CA2131130A1 (en) | 1994-08-30 | 1994-08-30 | Modulation of cellular activity |
| CA 2145605 CA2145605A1 (en) | 1995-03-27 | 1995-03-27 | Modulation of cellular activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL114914A0 true IL114914A0 (en) | 1995-12-08 |
Family
ID=25677464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL11491495A IL114914A0 (en) | 1994-08-30 | 1995-08-11 | Modulation of cellular activity |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0778776A1 (en) |
| JP (1) | JPH10504828A (en) |
| KR (1) | KR970705401A (en) |
| CN (1) | CN1130532A (en) |
| AP (1) | AP618A (en) |
| AU (1) | AU3159595A (en) |
| HU (1) | HUT76846A (en) |
| IL (1) | IL114914A0 (en) |
| WO (1) | WO1996006622A1 (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2141076T3 (en) | 1988-09-01 | 2000-03-16 | Bayer Ag | HUMAN RHINOVIRUS RECEPTOR PROTEIN INHIBITING VIRUS INFECTIVITY. |
| US6130202A (en) * | 1990-07-20 | 2000-10-10 | Bayer Corporation | Antiviral methods |
| AU739601B2 (en) * | 1991-07-03 | 2001-10-18 | Meditech Research Limited | Use of hyaluronan in gene therapy |
| AU727001B2 (en) * | 1995-12-01 | 2000-11-30 | Jagotec Ag | Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (GAGS) |
| CA2166155C (en) * | 1995-12-27 | 2008-02-05 | Eva Anne Turley | Agents binding to hyaluronic acid binding domains and the use thereof |
| US6875753B1 (en) | 1996-03-14 | 2005-04-05 | The Governors Of The University Of Alberta | Methods for cell mobilization using in vivo treatment with hyaluronan (HA) |
| CA2205771C (en) * | 1997-05-22 | 2002-05-14 | Hyal Pharmaceutical Corporation | Improved delivery of disease modifiers |
| DE59906391D1 (en) * | 1998-12-23 | 2003-08-28 | Esparma Gmbh | AGENT FOR PROTECTING THE SKIN CONTAINING HYDROLYSED HYALURONIC ACID |
| AU773984B2 (en) * | 1999-01-13 | 2004-06-10 | Alchemia Oncology Pty Limited | A composition and method for the enhancement of the efficacy of drugs |
| DK1140198T3 (en) | 1999-01-13 | 2008-03-10 | Alchemia Oncology Pty Ltd | Use of hyaluronan in the manufacture of a drug for enhancing the efficacy of cytotoxic drugs |
| WO2001080899A2 (en) * | 2000-04-20 | 2001-11-01 | Cangene Corporation | Rhamm peptide conjugates |
| US9066919B2 (en) | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
| AUPQ879500A0 (en) | 2000-07-14 | 2000-08-10 | Meditech Research Limited | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease |
| US7879824B2 (en) | 2001-07-31 | 2011-02-01 | Dermal Research Laboratories, Inc. | Methods of preventing or treating diseases and conditions using complex carbohydrates |
| EP1311276A4 (en) * | 2000-07-31 | 2007-09-12 | Dermal Res Lab Inc | Methods of preventing or treating diseases and conditions using complex carbohydrates |
| WO2003041723A1 (en) * | 2001-11-12 | 2003-05-22 | Reinmueller Johannes | Pharmaceutical applications of hyaluronic acid preparations |
| CA2502363A1 (en) * | 2002-11-12 | 2004-05-27 | Omeros Corporation | Irrigation solution and method for inhibition of tumor cell adhesion, pain and inflammation |
| ES2246694B1 (en) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | PEGILATED NANOPARTICLES. |
| ES2246695B1 (en) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | STIMULATING COMPOSITION OF THE IMMUNE RESPONSE THAT INCLUDES NANOPARTICLES BASED ON A COPYLIMER OF METHYL VINYL ETER AND MALEIC ANHYDRIDE. |
| JP5465431B2 (en) | 2005-07-27 | 2014-04-09 | アルケミア オンコロジー ピーティーワイ リミテッド | Treatment protocol with hyaluronan |
| BRPI0615619A2 (en) | 2005-09-07 | 2011-05-24 | Alchemia Oncology Pty Ltd | therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
| MX2009010400A (en) | 2007-03-30 | 2010-02-18 | Chu Sainte Justine | Method of determining risk of scoliosis. |
| ES2385995B2 (en) | 2011-01-10 | 2013-05-21 | Universidade De Santiago De Compostela | NANOCAPPSULES WITH POLYMER COVER |
| US9615750B2 (en) | 2012-06-14 | 2017-04-11 | Seno Medical Instruments, Inc. | Methods and compositions for carrier agents and clearing agents used in optoacoustic imaging systems |
| FR2994846B1 (en) | 2012-08-29 | 2014-12-26 | Vivacy Lab | COMPOSITION, STERILIZED, COMPRISING AT LEAST ONE HYALURONIC ACID AND MAGNESIUM ASCORBYL PHOSPHATE |
| FR3020570B1 (en) * | 2014-04-30 | 2017-07-21 | Pierre Fabre Dermo Cosmetique | ASSOCIATION OF A HYALURONIC ACID AND A SULFATE POLYSACCHARIDE |
| WO2019199385A1 (en) | 2018-04-13 | 2019-10-17 | Carrier Corporation | Method of defrosting a multiple heat absorption heat exchanger refrigeration system |
| CN120617530A (en) * | 2018-04-18 | 2025-09-12 | I.Com医疗有限责任公司 | High molecular weight hyaluronic acid for enhanced epithelial survival and body surface reconstruction |
| CN109481693B (en) * | 2018-12-14 | 2022-02-22 | 药大制药有限公司 | A kind of hyaluronic acid-nonoxynol ether conjugate, preparation method and application |
| CN118063833B (en) * | 2024-04-19 | 2024-06-28 | 四川兴泰普乐医疗科技有限公司 | Micro-crosslinking sodium hyaluronate gel and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4141973A (en) * | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
| CH666897A5 (en) * | 1983-10-11 | 1988-08-31 | Fidia Spa | NON-INFLAMMATORY HYALURONIC ACID FRACTIONS, PHARMACEUTICAL METHODS AND COMPOSITIONS. |
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| CA2061703C (en) * | 1992-02-20 | 2002-07-02 | Rudolf E. Falk | Formulations containing hyaluronic acid |
| GB9207949D0 (en) * | 1992-04-09 | 1992-05-27 | Univ Manitoba | Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility |
-
1995
- 1995-08-11 WO PCT/CA1995/000477 patent/WO1996006622A1/en not_active Ceased
- 1995-08-11 AU AU31595/95A patent/AU3159595A/en not_active Abandoned
- 1995-08-11 HU HU9701507A patent/HUT76846A/en unknown
- 1995-08-11 KR KR1019970701164A patent/KR970705401A/en not_active Ceased
- 1995-08-11 IL IL11491495A patent/IL114914A0/en unknown
- 1995-08-11 EP EP95927605A patent/EP0778776A1/en not_active Withdrawn
- 1995-08-11 JP JP8508371A patent/JPH10504828A/en active Pending
- 1995-08-14 AP APAP/P/1995/000756A patent/AP618A/en active
- 1995-08-29 CN CN95116995A patent/CN1130532A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HUT76846A (en) | 1997-12-29 |
| AP618A (en) | 1997-10-10 |
| AP9500756A0 (en) | 1995-10-31 |
| JPH10504828A (en) | 1998-05-12 |
| WO1996006622A1 (en) | 1996-03-07 |
| KR970705401A (en) | 1997-10-09 |
| CN1130532A (en) | 1996-09-11 |
| AU3159595A (en) | 1996-03-22 |
| EP0778776A1 (en) | 1997-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL114914A0 (en) | Modulation of cellular activity | |
| GB2324919B (en) | Modulation and frequency conversion by time sharing | |
| HU9702034D0 (en) | Heterocyclic compounds of leukocita-adhesion-inhibitor and vla-4-antagonist activity | |
| PL318295A1 (en) | Disposable cellular telephone | |
| ZA954656B (en) | High activity polyethylene catalysts | |
| GB2294169B (en) | Modulation and frequency conversion by time sharing | |
| IL133822A0 (en) | Aroylpiperazines for modulating sexual activity | |
| HU9702242D0 (en) | Inozitol-glykanes of inzulin-like activity | |
| SG79882A1 (en) | Protein having tpo activity | |
| EP0687940A3 (en) | Quasi-phasematched frequency converters | |
| PL332904A1 (en) | Dihydropyrones of improved antiviral activity | |
| EP1011654A4 (en) | A method of modulating cellular activity | |
| PL327732A1 (en) | Compounds of therapeutic activity | |
| HU9700071D0 (en) | Use of muramilpeptides | |
| GB2289852B (en) | Mobile | |
| HU9702480D0 (en) | New polymorphe modification of doxazosin-mesylate | |
| HU9702479D0 (en) | New polymorphe modification of doxazosin-mesylate | |
| ZA957223B (en) | Modulation of cellular activity | |
| PL311885A1 (en) | Protein of tpo activity | |
| PL317319A1 (en) | Oxidative amonolysis of alkylopyridines | |
| ZA989413B (en) | Determination of cellular growth abnormality | |
| GB9724134D0 (en) | Determination of cellular growth abnormality | |
| PL313849A1 (en) | Beta-aminoesters of o-hydrobenzylamides | |
| IL114944A0 (en) | Disposable cellular phone-set | |
| GB9215053D0 (en) | Enzyme catalyst |